

Summary Public Assessment Report

**Bimaprez
(bimatoprost)**

SE/H/2447/01/DC

Summary Public Assessment Report

Bimaprez
bimatoprost

Eye drops, solution, 0,1 mg/ml

This is a summary of the public assessment report (PAR) for Bimaprez. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Bimaprez and what is it used for?

The product is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance.

The reference medicine for the product is Lumigan 0,1 mg/ml, Eye drops, solution.

The company has provided additional own data to demonstrate therapeutic equivalence between the product and the reference medicine.

Bimaprez is an antiglaucoma preparation. It belongs to a group of medicines called prostamides.

Bimaprez is used to reduce high pressure in the eye. This medicine may be used on its own or with other drops called beta-blockers which also reduce pressure.

How does Bimaprez work?

Bimaprez is used to reduce high pressure in the eye. This medicine may be used on its own or with other drops called beta-blockers which also reduce pressure.

Your eye contains a clear, watery liquid that feeds the inside of the eye. This liquid is constantly being drained out of the eye and new liquid is made to replace it. If the liquid cannot drain out quickly enough, the pressure inside the eye builds up. This medicine works by increasing the amount of liquid that is drained. This reduces the pressure inside the eye. If high pressure is not reduced, it could lead to a disease called glaucoma and eventually damage your sight.

How is Bimaprez used?

The pharmaceutical form is eye drops, solution, applied to the eye.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Bimaprez have been shown in studies?

Because the product is a hybrid application and is considered to be therapeutically equivalent to the reference product Lumigan 0,1 mg/ml, Eye drops, solution, the benefits and risks are taken as being the same as those of the reference medicine.

What are the possible side effects from Bimaprez?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Bimaprez approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be similar to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Lumigan 0,1 mg/ml, Eye drops, solution, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Bimaprez?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Bimaprez

The full PAR for Bimaprez can be found on the following website: [MRI - Home](#). For more information about treatment with Bimaprez, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-07.